Related Experiment Video
Updated: Apr 27, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Novel pancreatic cancer vaccines could unleash the army within
1Gastrointestinal Tumor Program, Moffitt Cancer Center, Tampa, FL 33612, USA. Gregory.Springett@Moffitt.org.
Background:
Despite recent progress with novel chemotherapy regimens, pancreatic ductal adenocarcinoma remains the fourth leading cause of cancer death in the United States. Innovative approaches to treatment of this disease are needed to accelerate progress.
Methods:
A review was conducted of the results of 2 pancreatic cancer vaccine programs with results that have shown promise in early-phase clinical trials.
Results:
In a phase 2 trial, a cell-based allogeneic pancreatic cancer vaccine exploiting the hyperacute rejection response targeted against alpha-1,3 galactosyl epitopes (algenpantucel-L) has shown improvement in disease-free and overall survival rates in the adjuvant setting compared with a historical control. This vaccine has advanced to ongoing phase 3 trials. Compared with GVAX alone, a second whole-cell vaccine employing GM-CSF-expressing pancreatic cancer cells (GVAX) to enhance the antigen presentation in a priming phase followed by a Listeria-based vaccine targeting mesothelin in a boost phase improved survival rates. This vaccine platform is undergoing additional phase 2 testing.
Conclusions:
Allogenic whole-cell pancreatic adenocarcinoma vaccines show promise in early-phase trials and have the potential to improve survival rates by unleashing antitumor immunity.
Insights
Pancreatic cancer vaccines show promise. Two whole-cell vaccine approaches, algenpantucel-L and GVAX, demonstrated improved survival rates in early trials, offering new hope for pancreatic ductal adenocarcinoma treatment.
Area of Science:
- Oncology
- Immunotherapy
- Vaccine Development
Background:
- Pancreatic ductal adenocarcinoma is a leading cause of cancer death in the US.
- Current chemotherapy regimens have limited efficacy.
- Novel treatment strategies are urgently needed.
Purpose of the Study:
- To review promising pancreatic cancer vaccine programs.
- To evaluate early-phase clinical trial results.
Main Methods:
- Review of two distinct pancreatic cancer vaccine trials.
- Analysis of algenpantucel-L (cell-based, alpha-1,3 galactosyl epitopes) in phase 2 adjuvant setting.
- Evaluation of GVAX (GM-CSF-expressing cells) combined with a Listeria-based mesothelin vaccine in priming-boost strategy.
Main Results:
- Algenpantucel-L showed improved disease-free and overall survival in phase 2, advancing to phase 3.
- The GVAX platform demonstrated improved survival rates compared to GVAX alone.
- Both vaccine approaches exploit unique mechanisms to target pancreatic cancer.
Conclusions:
- Allogeneic whole-cell pancreatic cancer vaccines show potential.
- These vaccines may improve survival by activating antitumor immunity.
- Further clinical trials are warranted to confirm efficacy.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
06:16Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
Published on: December 7, 2019
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...